Literature DB >> 11520576

HTLV-1 structural proteins.

I Le Blanc1, M P Grange, L Delamarre, A R Rosenberg, V Blot, C Pique, M C Dokhélar.   

Abstract

HTLV-1 structural proteins do not appear to ensure virus transmission as efficiently as most other retrovirus structural proteins do, whereas all other retroviruses can be transmitted via either free virions or cell-to-cell contacts, infection by HTLV-1 by free virions is very inefficient, and effective infection requires the presence of HTLV-1 infected cells. This characteristic feature of HTLV-1 provides a unique tool which can be used to analyse retrovirus cellular transmission in the absence of simultaneous cell-free infection. Here we summarise what is known about HTLV-1 structural proteins and identify the questions about these proteins which remain to be answered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520576     DOI: 10.1016/s0168-1702(01)00278-7

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  12 in total

1.  Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag.

Authors:  Jingga Inlora; Vineela Chukkapalli; David Derse; Akira Ono
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.

Authors:  David Ghez; Yves Lepelletier; Sophie Lambert; Jean-Marie Fourneau; Vincent Blot; Sébastien Janvier; Bertrand Arnulf; Peter M van Endert; Nikolaus Heveker; Claudine Pique; Olivier Hermine
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations.

Authors:  Lee R Silverman; Andrew J Phipps; Andy Montgomery; Soledad Fernandez; Tomonori Tsukahara; Lee Ratner; Michael D Lairmore
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

4.  Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.

Authors:  Ana-Monica Pais-Correia; Martin Sachse; Stéphanie Guadagnini; Valentina Robbiati; Rémi Lasserre; Antoine Gessain; Olivier Gout; Andrés Alcover; Maria-Isabel Thoulouze
Journal:  Nat Med       Date:  2009-12-20       Impact factor: 53.440

Review 5.  Molecular aspects of HTLV-1 entry: functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors.

Authors:  Kathryn S Jones; Sophie Lambert; Manuella Bouttier; Laurence Bénit; Frank W Ruscetti; Olivier Hermine; Claudine Pique
Journal:  Viruses       Date:  2011-06-15       Impact factor: 5.048

Review 6.  Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.

Authors:  Michael D Lairmore; Rajaneesh Anupam; Nadine Bowden; Robyn Haines; Rashade A H Haynes; Lee Ratner; Patrick L Green
Journal:  Viruses       Date:  2011-07-12       Impact factor: 5.048

7.  Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging.

Authors:  José O Maldonado; Isaac Angert; Sheng Cao; Serkan Berk; Wei Zhang; Joachim D Mueller; Louis M Mansky
Journal:  Viruses       Date:  2017-07-19       Impact factor: 5.048

Review 8.  Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease.

Authors:  Veronique Lepoutre; Pooja Jain; Kevin Quann; Brian Wigdahl; Zafar K Khan
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

9.  Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  Front Microbiol       Date:  2012-12-11       Impact factor: 5.640

Review 10.  Molecular Studies of HTLV-1 Replication: An Update.

Authors:  Jessica L Martin; José O Maldonado; Joachim D Mueller; Wei Zhang; Louis M Mansky
Journal:  Viruses       Date:  2016-01-27       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.